Kenya Launches Long-Acting HIV Prevention Injection

By Moses Punyuah, Nairobi

Kenya has officially launched Lenacapavir, a groundbreaking long-acting injectable for HIV prevention, in a major boost to the country’s fight against new infections.

Presiding over the launch at Riruta Health Centre, Nairobi, Health Cabinet Secretary Aden Duale said the introduction of the injection marks a major milestone in strengthening HIV prevention strategies.

“This is a game-changer in our national HIV response. By expanding innovative prevention options, we are accelerating efforts to reverse new infections and protect vulnerable populations,” said Duale.

The CS noted that 1.4 million Kenyans are living with HIV, stressing the need for more effective prevention tools to curb transmission.

He disclosed that Lenacapavir will be administered twice a year and offered free of charge at selected public health facilities in priority counties, following a phased and structured rollout.

“The injectable meets all regulatory and safety standards and will be delivered through trained healthcare workers to ensure safe, equitable and effective access,” he added.

Kenya becomes one of the first countries globally to roll out Lenacapavir for HIV prevention, signalling growing international confidence in the country’s health systems.

The launch was attended by Medical Services PS Dr Ouma Oluga, NASCOP CEO Dr Andrew Mulwa, Dagoretti North MP Beatrice Elachi, and devel

opment partners.